SUNNYVALE, CA--(Marketwire - August 27, 2009) - Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces the sale of instruments used to identify allergens in affected individuals.
For allergy testing, allergens are printed onto proprietary glass substrates to form microarrays. Serum samples from individuals with allergies are then reacted with the microarrays to allow binding between the allergens and molecules present in the patient's blood stream. High-speed scanners read the microarrays to determine the nature of the allergic response in each individual. This same procedure can be used to decipher other immune and autoimmune conditions.
About Arrayit Corporation
Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
Safe Harbor Statement
Except for historical information contained herein, statements made in this
release that would constitute forward-looking statements may involve
certain risks and uncertainties. All forward-looking statements made in
this release are based on currently available information and the Company
assumes no responsibility to update any such forward-looking statement. The
following factors, among others, may cause actual results to differ
materially from the results suggested in the forward-looking statements.
The factors include, but are not limited to, risks that may result from
changes in the Company's business operations; our ability to keep pace with
technological advances; significant competition in the biomedical business;
our relationships with key suppliers and customers; quality and consumer
acceptance of newly introduced products; market volatility;
non-availability of product; excess inventory; price and product
competition; new product introductions, the outcome of our legal disputes;
the possibility that the review of our prior filings by the SEC may result
in changes to our financial statements; and the possibility that
stockholders or regulatory authorities may initiate proceedings against
Arrayit and/or our officers and directors as a result of any restatements.
Risk factors associated with our business, including some of the facts set
forth herein, are detailed in the Company's Form 10-K for the fiscal year
ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended
March 31, 2008 and Form 10-Q for the fiscal third quarter ended September
30, 2008.
